Intravenous Thrombolysis and NOAC

NCT06749834 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Phase

Phase 3

Started

2025-01-27

Last updated

2025-02-24

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

Intravenous thrombolysis →

Intravenous thrombolysis: Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).

Study summary

New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF). Despite the effectiveness of NOACs in preventing thromboembolic events, approximately 1% to 2% of patients taking NOACs experience an ischemic stroke annually. Intravenous thrombolysis is an important means of treating acute ischemic stroke (AIS). However, due to concerns about the risk of symptomatic intracranial hemorrhage (sICH) or other severe bleeding complications, current guidelines still consider the use of NOACs within 48 hours before symptom onset as a contraindication to intravenous thrombolysis. Epidemiological data suggest that this may result in up to 18% of AF patients being unable to receive intravenous thrombolysis when they have an AIS episode.

Previous animal experiments have shown that NOACs do not increase the risk of hemorrhagic transformation after intravenous thrombolysis. Pharmacokinetic studies have demonstrated that 24 to 48 hours after taking NOACs, the anti-Xa level in patients is relatively low (\<0.5 U/mL). In recent years, multiple retrospective studies and meta-analyses have shown that prior use of NOACs does not increase the risk of sICH in AIS patients receiving intravenous thrombolysis, and there are no significant differences in functional outcomes at 3 months. With solid pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-NOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-NOAC.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Patients with clinical signs of acute ischemic stroke within 24 hours of onset or awakening with stroke (if within 24 hours from the midpoint of sleep). Patients with AIS within 4.5-24 hours of onset must meet the IVT inclusion criteria specified in the guideline 2. Patients with new oral anticoagulants usage within 4-48 hours of onset; 3. Patients ≥ 18 years old 4. Informed consent has been obtained depending on local ethics requirements. Exclusion Criteria: 1. Intended to proceed to endovascular treatment 2. With APTT \>40s 3. Pre-stroke mRS score \> 2 4. Contraindications for IVT： 1\) Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hematoma, etc.) 2) Previous history of intracranial hemorrhage 3) Severe head trauma or stroke history within the last 3 months 4) Intracranial tumors, giant intracranial aneurysms 5) Intracranial or spinal surgery within the recent 3 months 6) Major surgical procedures within the last 2 weeks 7) Gastrointestinal or urinary tract bleeding within the last 3 weeks 8) Active visceral bleeding 9) Aortic arch dissection 10) Arterial puncture in a site within the last 1 week that is not easy to compress and stop bleeding 11) Elevated blood pressure: Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg 12) Acute bleeding tendency, including platelet count \< 100 × 10⁹/L or other conditions 13) Received low-molecular-weight heparin treatment within 24 hours 14) Oral anticoagulants (warfarin) with INR \> 1.7 or PT \> 15 s 15) Blood sugar \< 2.8 or \> 22.22 mmol/L 16) Head CT or MRI indicates large-area infarction (infarction area ≥ 1/3 of the middle cerebral artery supply area) (4) The judgment is left to the discretion of the investigator

Primary outcome measure(s)

Excellent recovery assessed by the ratio of modified Rankin Scale (mRS) score of 0-1 (%) at 90 ± 7 days — 90 ± 7 days
mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome

Trial sites (2)

Facility	City	Region	Status
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou	Hangzhou	Zhejiang	Not Yet Recruiting
The First People's Hospital of Wenling	Taizhou	Zhejiang	Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Microneedle Intra-Arterial Injection for Retinal Artery Occlusion Recruiting

Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease Recruiting

Multicenter Study on the Use of Intraoperative OCT in the Diagnosis and Management of Lens Diseases Active, not recruiting

China Longitudinal Aging and Cognitive Impairment Study Recruiting

Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients Starting soon

Other trials for the same condition

Telemedicine-supported Management for Acute Ischemic Stroke Recruiting

OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion Recruiting

Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch Starting soon

Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy Recruiting

Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06749834 on ClinicalTrials.gov ↗ ← All trials in China